Chemical apparatus and process disinfecting – deodorizing – preser – Analyzer – structured indicator – or manipulative laboratory... – Structured visual or optical indicator – per se
Reexamination Certificate
2011-08-30
2011-08-30
Azpuru, Carlos (Department: 1617)
Chemical apparatus and process disinfecting, deodorizing, preser
Analyzer, structured indicator, or manipulative laboratory...
Structured visual or optical indicator, per se
Reexamination Certificate
active
08007737
ABSTRACT:
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In each of these instances, antioxidants are utilized to prolong product integrity.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3959078 (1976-05-01), Guire
patent: 4350160 (1982-09-01), Kolesov et al.
patent: 4366819 (1983-01-01), Kaster
patent: 4368736 (1983-01-01), Kaster
patent: 4624257 (1986-11-01), Berggren et al.
patent: 4722906 (1988-02-01), Guire
patent: 4733665 (1988-03-01), Palmaz
patent: 4739762 (1988-04-01), Palmaz
patent: 4776337 (1988-10-01), Palmaz
patent: 4917090 (1990-04-01), Berggren et al.
patent: 4917091 (1990-04-01), Berggren et al.
patent: 5229172 (1993-07-01), Cahalan et al.
patent: 5234447 (1993-08-01), Kaster et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5350800 (1994-09-01), Verhoeven et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5924997 (1999-07-01), Campbell
patent: 5932243 (1999-08-01), Fricker et al.
patent: 6099562 (2000-08-01), Ding et al.
patent: 6106530 (2000-08-01), Harada
patent: 6120536 (2000-09-01), Ding et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6245026 (2001-06-01), Campbell
patent: 7029492 (2006-04-01), Mitsudou
patent: 2003/0204239 (2003-10-01), Carlyle et al.
patent: 1364628 (2003-11-01), None
patent: WO 98/33443 (1998-08-01), None
patent: WO 2005/016399 (2005-02-01), None
Faxon, David, http://books.google.com/books?id=K1oUdEZLAKAC&dq=restenosis:+A+guide+to+therapy+Faxon&printsec=frontcover&source=bn&hl=en&sa=X&oi=book—result&resnum=8&ct=result#PPA113,M1, “Restenosis: A Guide to Therapy”, Informa Health Care, pp. 113-122, 2001.
Tardif, J-C., “Prevention of Restenosis with Antioxidants: Mechanisms and implications” See Abstract, Am J. Cardiovas Drugs 2002, 2(5):323-34.
Probucol, Wilipedia, 2008.
Tardiff et al, Am. j. Cardiovasc Drugs, 2002.
Beutler, E. “Cladribine (2-chlorodeoxyadenosine)”, The Lancet, vol. 340, p. 952 (Oct. 1992).
Brehm, B., et al. “β-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells”, Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S401-S-403 (2000).
Brehm, B., et al. “Chronically Elevated Endothelin-1 Concentrations Modulate the β-Adrenergic Receptor System In Vitro and In Vivo”, Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S157-159 (2000).
Carson, D., et al. “DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death”, Experimental Cell Research 164 p. 273-281 (1986).
Clowes and Schwartz, “Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery”, Cir. Res. 56: 139-145 (1985).
Deroanne, C., et al. “Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular endothelial Growth Factor Signaling”, Oncogene 21, p. 427-436 (2002).
Lang, R., et al. “Effects of Okadaic Acid and ATPγS on Cell Length and CA2+—Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci”, Br. J. Pharmacol. 104, p. 331-336 (1991).
Serruys, P. et al. “Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized double-Blind Placebo-Controlled Trial”, Circulation of the Journal of the American Heart Association, 88 p. 1588-1601 (1993).
Serruys, P., et al. “Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study”, Circulation of the American Heart Association, vol. 93(3) p. 412-422 (1996).
Seto, S., et al. Mechanism of Deoxyadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes, J. Clin. Invest. vol. 75 p. 377-383 (1985).
Wiley and Sons, “Modern Fluoropolymers” High Performance Polymers for Diverse Applications, Wiley Series in Polymer Science p. 77-90 (1997).
Woo, S., et al. “Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors”, J. Med. Chem. 45, p. 2877-2885 (2002).
Yokoi, H., et al. “Effectiveness of an Antioxidant in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty Restenosis Trial”, JACC vol. 30, No. 4 p. 855-862 (1997).
Campbell & Campbell, “Phenotypic Modulation of Smooth Muscle Cells in Primary Culture”, (Table of Contents), Chapter 2, vol. 1, pp. 39-52 (1985).
Campbell & Campbell, “Cell Biology of Smooth Muscle in Culture: Implications for Atherogenesis”, Inter. Angio, 6 pp. 73 (1987.
Carrera, C., et al. “Potent Toxicity of 2-Chlorodeoxyadenosine Toward Human Monocytes in Vitro and in Vivo”, J. Clin. Invest. vol. 86, pp. 1480 (1990).
Carson, D, et al. “Specific Toxicity of 2-Chlorodeoxyadenosine Toward Resting and Proliferating Human Lymphocytes”, Blood vol. 62, pp. 737 (1983).
Edelman, E., et al. “Pathobiologic Responses to Stenting”, American journal of Cardiology vol. 91, Issue 7, Suppl. 1 (Apr. 1998) pp. 4E-6E.
Franklin, S., et al. “Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials”, Coronary Artery Disease, vol. 4, No. 3 (Mar. 1993).
Mak, K., et al. “Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization”, Department of Cardiolog, Cleveland Clinical Foundation, Ohio p. 255 (1991).
Pompa, J., et al. “Clinical Trials of Restenosis After Coronary Angioplasty”, Journal of the American Heart Association (Circulation), 84:1426-1436 (1991).
Tanaka, H., et al. “Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta after Balloon Injury”, Circulation vol. 88 p. 1788 (19930.
Teirstein, P., et al. “Catheter-Based Radiotherapy to Inhibit Restenosis after Coronary Stenting”, New England Journal of Medicine, vol. 336, p. 1679 (1997).
Yokoi, H., et al. “Effectiveness of an Antioxidant in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty Restenosis Trial”, JACC, vol. 30, No. 4 p. 855 (1997).
Ajroldi, G. et al., “Fluoroelastomers-dependence of relaxation phenomena on compositions”, Polymer, 30, No. 12, (1989): 2180-2187.
Berk, B.C. et al., “Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty”, J. Am. Coll. Cardio. vol. 17, No. 6, pp. 111B-117B, 1991.
Chang, M.W. et al., “Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty”, J. Clin. Invest. vol. 96, pp. 2260-2268, 1995.
Clowes, A.W. et al., “Suppression by heparin of smooth muscle cell proliferation in injured arteries”, Nature, vol. 265, pp. 625-626, 1977.
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury”, Laboratory Investigation, vol. 52, No. 6, pp. 611-616, 1985.
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury IV. Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration”, Circulation Research, vol. 58, No. 6, pp. 839-845, 1986.
Colburn, M.D. et al., “Dose responsive suppression of myointimal hyperplasia by dexamethasone”, J. Vasc. Surg. vol. 15, No. 3, pp. 510-518, 1992.
Curr
Azpuru Carlos
Evens Carl J.
Wyeth
LandOfFree
Use of antioxidants to prevent oxidation and reduce drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antioxidants to prevent oxidation and reduce drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antioxidants to prevent oxidation and reduce drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779699